Health Ministry Proposes Incorporation of Good Storage and Distribution Practices (GSDP) into Drugs Rules, 1945

Ø  GSDP Framework to Enhance Regulatory Oversight and Accountability in Pharmaceutical Supply Chain

Ø  Proposed Measures to Ensure Quality, Safety and Integrity of Pharmaceutical Products from Manufacturer to Patient

The Union Ministry of Health and Family Welfare has proposed incorporating Good Storage and Distribution Practices (GSDP) guidelines for pharmaceutical products into the Drugs Rules, 1945, to ensure quality and safety throughout the pharmaceutical supply chain.

Key Highlights

1.    Objective: To maintain the quality, safety, efficacy and integrity of pharmaceutical products from the manufacturer or importer up to their supply to the patient.

2.    Regulatory Framework: The proposal builds upon GSDP guidelines developed by the Central Drugs Standard Control Organisation (CDSCO).

3.    Coverage: GSDP requirements will cover all major stages of pharmaceutical distribution, including:

o    Procurement and purchasing.

o    Storage and warehousing.

o    Distribution and transportation.

o    Documentation and record-keeping.

4.    Supply Chain Risks: The guidelines aim to prevent:

o    Deterioration of pharmaceutical products.

o    Contamination and product mix-ups.

o    Falsification of medicines.

o    Diversion and unauthorised distribution.

5.    Stakeholders Covered: The framework will enhance accountability among:

o    Manufacturers and importers.

o    Wholesalers and distributors.

o    Stockists and other entities involved in pharmaceutical distribution.

6.    Storage and Transportation: Pharmaceutical products must be maintained under specified quality and environmental conditions throughout storage and transportation.

7.    Regulatory Oversight: Incorporation into the Drugs Rules, 1945, will strengthen inspection, monitoring and enforcement by Central and State drug-control authorities.

8.    Traceability and Accountability: Improved documentation, record-keeping and traceability will facilitate regulatory supervision and accountability across the distribution chain.

Expected Impact

·         Strengthen India's pharmaceutical quality-management system.

·         Minimise risks of deterioration, contamination, falsification and diversion.

·         Ensure that product quality established during manufacturing is maintained throughout storage and distribution.

·         Improve availability of medicines of assured quality to patients and healthcare providers.

Effect of the Proposed Amendment: GSDP requirements will become part of the statutory regulatory framework under the Drugs Rules, 1945, strengthening quality control and accountability across the pharmaceutical supply chain, from manufacturing or importation to the final patient.

 

[ABS News Service/20.11.2026]

The Union Ministry of Health and Family Welfare has proposed the incorporation of Good Storage and Distribution Practices (GSDP) guidelines for pharmaceutical products into the Drugs Rules, 1945. The proposal aims to ensure that the quality, safety, efficacy and integrity of pharmaceutical products are maintained throughout the distribution chain, from the manufacturer or importer to the point of supply to the patient.

The proposed framework builds upon the GSDP guidance developed by the Central Drugs Standard Control Organisation (CDSCO). The guidelines seek to ensure the quality and identity of pharmaceutical products at every stage of the distribution process, including procurement, purchasing, storage, distribution, transportation, documentation and record-keeping.

Maintaining appropriate storage and distribution conditions is essential to preserving the quality and integrity of pharmaceutical products beyond the manufacturing stage. The proposed GSDP framework seeks to address potential risks associated with their handling and movement across the supply chain, including deterioration, contamination, mix-ups, falsification, diversion and unauthorised distribution.

The incorporation of GSDP requirements into the Drugs Rules, 1945, is expected to strengthen the regulatory framework governing pharmaceutical distribution and support effective regulatory oversight, inspection and enforcement by the Central and State drug-control authorities. It will also promote robust documentation, record-keeping and traceability, while enhancing accountability among manufacturers, importers, wholesalers, distributors, stockists and other entities involved in the distribution process.

The proposed guidelines will further strengthen assurance that pharmaceutical products remain within specified quality and environmental conditions during storage and transportation, thereby reducing the risk of deterioration, contamination, mix-ups, falsification, diversion and unauthorised distribution. This will support the availability of pharmaceutical products of assured quality to patients and healthcare providers.

The proposed amendment represents an important step towards strengthening India's pharmaceutical quality-management system and ensuring that the quality established at the manufacturing stage is maintained throughout the supply chain until the product reaches the patient.

Stakeholders and members of the public are invited to submit their objections and suggestions, if any, to the Under Secretary (Drugs Regulation), Ministry of Health and Family Welfare, Government of India, U-6, Work Hall, C Wing, First Floor, Kartavya Bhawan-1, New Delhi - 110001, or via email at drugsdiv-mohfw[at]gov[dot]in.